1. Department of Health and Human Services, Public Health Service. Summary Basis for Approval. Food and Drug Administration, Centre for Drugs and Biologics.
2. Rudnick, S. Orthoclone OKT®3 (Muromonab-CD3) manufacture and quality control. Presented at Coming into Compliance: Biotechnology Process Validation and Regulation, New York City, 10 May 1988.
3. Williams, A. N. Virus removal validation studies for Orthoclone OKT®3 purification process. Oral presentation at West Coast Chapter Parenteral Drug Association, Biotechnology Process Validation Meeting, 29–30 March 1990, San Francisco, CA.
4. U.S.FDA. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals. Congressional Consumer, and International Affairs Staff (HFB-142), Park Building, Room 1–58, 5600 Fishers Lane, Rockville, MD 20857, USA, November 1987.
5. The case of the case study;McCormick;Bio/technology,1991